KLUS Pharma has been committed to the discovery and expansion of novel therapeutics for various diseases since it was founded in 2014. We focus on developing novel biologics, including monoclonal antibodies, multi-specific antibodies, and antibody-drug conjugates (ADC) for the treatment of cancer as well as cardiovascular disease and other severe diseases. Our platforms for antibody discovery, including hybridoma technology and phage display, create promising ways to expedite the movement of high-quality biologic drugs from bench to market. We work close...Learn more>>
Our Mission

At KLUS, our mission is to bring better health and a better life to our patients and their family. We pursue and provide safer biologic therapeutics to create a better world.

Our Science

Biologics discovery platform: We have established a high-throughput hybridoma platform, a high-capacity fully human antibody phage display library, and a bi-specific antibody design and clone platform. We have full abilities to evaluate affinity, stability, specificity and in vitro efficacy of antibody candidates. 

Learn more>>
  • Add: 8 Clarke Drive, Suite 4, Cranbury, New Jersey 08512
  • Email: Admin@kluspharma.com
  • Phone: (+ 001) 609-662-1913
  • Fax: (+ 001) 609-662-1918